How effective is Sotorasib in treating KRAS G12C mutations?

Sotorasib is the first approved targeted therapy targeting KRAS G12C mutations and has shown good therapeutic effects in patients with non-small cell lung cancer (NSCLC). KRASgene is one of the earliest oncogenes discovered, among which G12C mutation is a common subtype, accounting for about 13% of NSCLC KRAS mutations. In the past, due to the special structure of the KRAS protein, it has been regarded as an "undruggable" target. The advent of sotorasiib breaks this limitation and brings new hope to lung cancer patients with positive KRAS G12C mutation.

In pivotal clinical studies, such as the CodeBreaK 100 trial, sotoraxib has achieved significant efficacy in patients with advanced NSCLC who have previously received chemotherapy or immunotherapy. Data show that the patient’s objective response rate (ORR) reached approximately 37%, and the disease control rate (DCR) exceeds 80%, and the median progression-free survival (PFS) is close to 7 months. These data demonstrate that sotorasiib can effectively block the abnormal signaling pathways caused by KRAS G12C mutations, thereby inhibiting tumor growth.

Another advantage of sotoraxib is that it is administered orally, is convenient to treat, and is well tolerated by most patients. Common adverse reactions include diarrhea, fatigue, nausea, and elevated transaminases, but are usually mild to moderate and can be alleviated by dose adjustment or symptomatic treatment. Compared with traditional chemotherapy, the side effects of sotoraxib are easier to manage and the quality of life is significantly improved.

In general, sotorasiib, as a precise treatment for patients with KRAS G12C mutationNSCLC, has clear efficacy and controllable safety. With the advancement of more research, the application prospects of sotorasiib in combination therapy and other KRAS mutation-related tumors are also very broad, indicating that more breakthroughs will be made in the field of KRAS targeted therapy.

Reference materials:https://www.lumakras.com/